FDA Calls for Restrictions on Ovarian Cancer Drug Rubraca Due to High Mortality Rates
The FDA is seeking restrictions on the ovarian cancer drug Rubraca, following data indicating it may increase the risk of death in some patients.
The FDA is seeking restrictions on the ovarian cancer drug Rubraca, following data indicating it may increase the risk of death in some patients.
A new study reveals a link between some ovarian cancer drugs and an increased risk of blood cancers, like leukemia.